Características y supervivencia de adultos con cáncer diferenciado de tiroides en un hospital de Perú

Luz Morales-Concha; Iván Huamani-Linares; Katy Saihua-Palomino; Edward Luque Florez; Alexi Chávez Echevarría; Ramiro Jorge Tupayachi Palomino; Carlos Antonio Zea Nuñez; Christian R. Mejia; Noé Atamari-Anahui

doi:10.17843/rpmesp.2024.413.13378

Authors

Luz Morales-Concha Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú https://orcid.org/0000-0002-3974-0677
Iván Huamani-Linares Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. ASOCIEMH-CUSCO, Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. https://orcid.org/0000-0002-7113-6752
Katy Saihua-Palomino Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. ASOCIEMH-CUSCO, Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. https://orcid.org/0000-0003-2776-2868
Edward Luque Florez Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. Departamento de Cirugía General, Hospital Antonio Lorena, Cusco, Perú. https://orcid.org/0000-0002-2958-5538
Alexi Chávez Echevarría Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. Hospital Nacional Adolfo Guevara Velasco – EsSalud, Cusco, Perú. https://orcid.org/0009-0003-7292-7315
Ramiro Jorge Tupayachi Palomino Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. Hospital Nacional Adolfo Guevara Velasco – EsSalud, Cusco, Perú. https://orcid.org/0000-0001-8263-9008
Carlos Antonio Zea Nuñez Facultad de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Perú. Hospital Nacional Adolfo Guevara Velasco – EsSalud, Cusco, Perú. https://orcid.org/0000-0002-8672-5250
Christian R. Mejia Universidad Continental, Huancayo, Perú. Asociación Médica de Investigación y Servicios en Salud, Lima, Perú. https://orcid.org/0000-0002-5940-7281
Noé Atamari-Anahui Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Perú https://orcid.org/0000-0001-8283-6669

DOI:

https://doi.org/10.17843/rpmesp.2024.413.13378

Keywords:

Thyroid Neoplasms, Survival Rate, Mortality, Peru

Abstract

This study aimed at studying the clinical and anatomopathological characteristics, treatment and survival of patients with differentiated thyroid cancer. A retrospective cohort study was conducted with data from 150 patients from a Peruvian hospital between the years 2010 to 2020. Characteristics and survival (Kaplan-
Meier method) were described. The mean age was 48.3 years, 130 participants (86.7%) were women and the most frequent histologic type was papillary 94.6%. Of the participants, 74.2% had TNM stage I, 70.7% had total thyroidectomy and 68.7% received radioactive iodine. Overall survival at 5 years was 89.3%, being lower in those with TNM stage IV and higher in those who used radioactive iodine. In conclusion, in a hospital in Cusco, differentiated thyroid cancer was more frequent in women and survival was lower compared to reports from other countries.

Downloads

Download data is not yet available.

References

Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401(10387):1531-44. doi: 10.1016/S0140-6736(23)00020-X.

Seib CD, Sosa JA. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48(1):23-35. doi: 10.1016/j.ecl.2018.10.002.

Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264-72. doi: 10.1016/S2213-8587(22)00035-3.

World Health Organization. Perú. Cancer today [Internet]. [citado 13 de mayo de 2024]. Disponible en: http://gco.iarc.fr/today/home.

Borges AK da M, Ferreira JD, Koifman S, Koifman RJ. Differentiated thyroid carcinoma: a 5-years survival study at a referral hospital in Brazil. Rev Saude Publica. 2019;53:106. doi: 10.11606/S1518-8787.2019053001496.

Sastre Marcos J, Aznar S, Álvarez V, Torres B, Delgado M, González J, et al. Resultados del seguimiento de pacientes con carcinoma diferenciado de tiroides en Castilla-La Mancha (2001-2015). Estudio CADIT-CAM. Endocrinol Diabetes Nutr. 2019;66(3):164-72. doi: 10.1016/j.endinu.2018.10.005.

Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341-9. doi: 10.1089/thy.2010.0178.

Mendoza Montoya LK, Cornejo Arenas S del P, Solís Villanueva JE, García Ramos FE, Lazo Porras M. Características clínicas, ecográficas y citohistológicas de nódulos tiroideos con sospecha de malignidad en un servicio de endocrinología de un hospital público. Rev Soc Peru Med Interna. 2019;32(2):48-53. doi: 10.36393/spmi.v32i2.217.

Paz-Ibarra J, Britto S, Tejeda N. Cáncer de tiroides: Tópicos Selectos. 1 ed. Lima, Perú: Fondo Editorial Comunicacional; 2022. 129 p.

Morales-Guzmán-Barrón R, Tessy Tairo-Cerrón, Torres-Vega F, Cano-Pérez R, Farfán-García J, Michahelles-Barreno C, et al. Rastreo de tejido tiroideo positivo y tiroglobulina negativa en pacientes con cáncer diferenciado de tiroides sometidos a tiroidectomía total: reporte de casos. Rev Soc Peru Med Interna. 2018;31(1):24-6. doi: 10.36393/spmi.v31i1.42.

Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?. Thyroid. 2017;27(6):751-6. doi: 10.1089/thy.2017.0102.

Arias-Ortiz NE, Guzmán-Gallego EA. Características clínicas del cáncer de tiroides en Manizales, Colombia, 2008-2015. Rev Peru Med Exp Salud Pública. 2020;37(2):287-91. doi: 10.17843/rpmesp.2020.372.4892.

Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. 2016;17(1):38. doi: 10.1186/s12875-016-0440-0.

Wang P, Lv L, Qi F, Qiu F. Increased risk of papillary thyroid cancer related to hormonal factors in women. Tumour Biol. 2015;36(7):5127-32. doi: 10.1007/s13277-015-3165-0.

Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Overvad K, et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst. 2014;106(6):dju097. doi: 10.1093/jnci/dju097.

Solis-Pazmino P, Salazar-Vega J, Lincango-Naranjo E, Garcia C, Koupermann GJ, Ortiz-Prado E, et al. Thyroid cancer overdiagnosis and overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador. BMC Cancer. 2021;21(1):42. doi: 10.1186/s12885-20-07735-y.

Kim SH, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, et al. Differences in the Recurrence and Survival of Patients with Symptomatic and

Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-Up. Thyroid. 2016;26(10):1472-9.

doi: 10.1089/thy.2016.0238.

Atamari-Anahui N, Morales-Concha L, Moncada-Arias AG, De-Los- Ríos-Pinto A, Huamanvilca-Yépez Y, Pereira-Victorio CJ, et al. National trends in prevalence and mortality rates of thyroid cancer using data from the Ministry of Health of Peru. Medwave. 2019;19(4):e7631. doi: 10.5867/medwave.2019.04.7631.

Collins RA, McManus C, Kuo EJ, Liou R, Lee JA, Kuo JH. The impact of social determinants of health on thyroid cancer mortality and time to treatment. Surgery. 2024;175(1):57-64. doi: 10.1016/j.surg.2023.04.062.

Ciarallo A, Rivera J. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update. Am J Roentgenol. 2020;215(2):285-91. doi: 10.2214/AJR.19.22626.

Salazar MR, Regalado-Rafael R, Navarro JM, Montanez DM, Abugattas JE, Vidaurre T. The role of the National Institute of Neoplastic Diseases in the control of cancer in Peru. Rev Peru Med Exp Salud Publica. 2013;30(1):105-12. doi: 10.1590/s1726-46342013000100020.

Vidaurre T, Santos C, Gómez H, Sarria G, Amorin E, López M, et al. The implementation of the Plan Esperanza and response to the imPACT Review. Lancet Oncol. 2017;18(10):e595-606. doi: 10.1016/S1470-2045(17)30598-3.